Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Aryl Alcohol. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN1498273A details microbial reduction for chiral alcohols. Enhances purity and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel Heck reaction method using solid base resin for 2-aryl allyl alcohol. Reduces cost and environmental impact for high-purity pharmaceutical intermediate manufacturing.
Patent CN113979975A details a metal-free chiral phosphoric acid catalyzed kinetic resolution for high-purity pharmaceutical intermediates, offering significant cost reduction and supply chain reliability.
Patent CN113087691A details a Pd-catalyzed kinetic resolution for chiral aryl tertiary alcohols. Discover cost-effective routes for high-purity pharmaceutical intermediates.
Patent CN112481226A discloses solvent-tolerant ADH mutants enabling 99.9% conversion for chiral diaryl alcohols, offering a green alternative to costly chemical synthesis.
Patent CN101857887B enables high-purity aryl alcohol production. Reduced reaction time and cofactor costs ensure reliable supply chain performance.
Patent CN100554403C reveals Microbacterium oxydans for high-purity chiral alcohol. Offers cost reduction and supply chain reliability for pharma intermediates.
Patent CN116574072A details a green visible-light method for 2,5-diaryl furans. Offers cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN105732249A details a high-ee Rh-catalyzed route for Escitalopram intermediates. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN112481226B details solvent-tolerant ADH mutants for scalable production of chiral alcohols, offering significant cost reduction and supply chain reliability for pharma intermediates.
Patent CN101085990A reveals chemo-enzymatic route for high-purity chiral alcohols. Enables cost reduction and supply chain reliability for pharmaceutical intermediates.
Analysis of patent CN101085990B reveals a chemo-enzymatic route for high-purity chiral alcohols. This method offers significant supply chain stability and cost reduction advantages for pharmaceutical intermediate manufacturing.
Patent CN108359649A reveals high-selectivity alcohol dehydrogenase mutants for synthesizing chiral biaryl alcohols, offering cost reduction and supply reliability.
Patent CN112110800A reveals electrochemical synthesis avoiding metal catalysts. Offers cost-effective pharma intermediate production with high purity.
Patent CN106995374A reveals catalyst-free oxygen oxidation for nitroaromatic acids. Delivers high purity, cost reduction, and scalable supply chain solutions.
Patent CN113845427B reveals a green visible light method for aryl compounds. This report analyzes cost reduction and supply chain reliability for fine chemical intermediates manufacturing.
Patent CN106995374B enables catalyst-free oxygen oxidation for nitroaromatic acids. Delivers high purity, reduced waste, and reliable supply chain for pharmaceutical intermediates.
Patent CN111094557B details novel ADH mutants enabling cost-effective, high-ee biocatalytic synthesis of chiral biaryl alcohols for antihistamine drugs.
Patent CN101857887A reveals a cell-free extract method for high-purity aryl alcohols, offering significant cost and time advantages for pharmaceutical manufacturing.
Novel copper-catalyzed one-step synthesis of E-configured aryl-substituted homoallyl alcohols. High yield, mild conditions, scalable for API intermediates.